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Platelet 12-Lipoxygenase Activation via Glycoprotein VI
Involvement of Multiple Signaling Pathways in Agonist Control of
H(P)ETE Synthesis
Marcus J. Coffey, Gavin E. Jarvis, Jonathan M. Gibbins, Barbara Coles, Natasha E. Barrett,
Oliver R.E. Wylie, Valerie B. O’Donnell
Abstract—Lipoxygenases (LOX) contribute to vascular disease and inflammation through generation of bioactive lipids,
including 12-hydro(pero)xyeicosatetraenoic acid (12-H(P)ETE). The physiological mechanisms that acutely control
LOX product generation in mammalian cells are uncharacterized. Human platelets that contain a 12-LOX isoform
(p12-LOX) were used to define pathways that activate H(P)ETE synthesis in the vasculature. Collagen and
collagen-related peptide (CRP) (1 to 10 g/mL) acutely induced platelet 12-H(P)ETE synthesis. This implicated the
collagen receptor glycoprotein VI (GPVI), which signals via the immunoreceptor-based activatory motif (ITAM)-
containing FcR chain. Conversely, thrombin only activated at high concentrations ( 0.2 U/mL), whereas U46619 and
ADP alone were ineffective. Collagen or CRP-stimulated 12-H(P)ETE generation was inhibited by staurosporine, PP2,
wortmannin, BAPTA/AM, EGTA, and L-655238, implicating src-tyrosine kinases, PI3-kinase, Ca2 mobilization, and
p12-LOX translocation. In contrast, protein kinase C (PKC) inhibition potentiated 12-H(P)ETE generation. Finally,
activation of the immunoreceptor tyrosine-based inhibitory motif (ITIM)–containing platelet endothelial cell adhesion
molecule (PECAM-1) inhibited p12-LOX product generation. This study characterizes a receptor-dependent pathway
for 12-H(P)ETE synthesis via the collagen receptor GPVI, which is negatively regulated by PECAM-1 and PKC, and
demonstrates a novel link between immune receptor signaling and lipid mediator generation in the vasculature. (Circ
Res. 2004;94:1598-1605.)
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Lipoxygenases (LOX) catalyze lipid hydroperoxide for-mation from unsaturated fatty acids.1 Many LOX iso-
forms are found in the vasculature: some constitutive (eg,
p12-LOX in platelets, 5-LOX in neutrophils), others cyto-
kine-inducible (eg, 15-LOX by interleukin-4 (IL-4) in mono-
cytes). Compelling evidence exists for critical involvement of
LOXs in vascular and inflammatory diseases including ath-
erosclerosis, cancer, hypertension, and diabetes.2–13
Cellular LOXs require direct activation before product
generation occurs. Typically, this requires (1) oxidation of the
ferrous iron to an intermediate that abstracts hydrogen from
unsaturated lipid and (2) translocation of the cytosolic en-
zyme to nuclear or plasma membrane. This activation is
separate from simple regulation of LOX by fatty acid supply,
and its requirement for H(P)ETE synthesis is supported by
the following evidence: (1) Ca2 stimulates membrane bind-
ing and arachidonate oxidation by purified 15-LOX in vitro;
(2) LOX product generation (in response to Ca2 ionophore)
is inhibited by membrane translocation inhibitors; and (3)
15-LOX in human monocytes oxidizes membrane-bound
arachidonate after Ca2 mobilization, independently of
PLA2.14–16 Currently, little is known regarding control of
LOX in cells by acute mechanisms. Most studies activate
LOX turnover by addition of arachidonate substrate with/
without Ca2 ionophore.17,18 These studies implicate Ca2-
dependent translocation, serine and tyrosine phosphorylation,
and LOX association with accessory proteins such as 5-li-
poxygenase activating protein (FLAP), although their in-
volvement in LOX activation using physiological agonists is
not established.18–23 Acute activation of LOXs has been
reported for neutrophil 5-LOX by fMLP and p12-LOX in
platelets by collagen; however, the receptors involved and
intracellular signaling pathways remain uncharacterized.24–27
Additionally, modulation of LOX activity within cells by
agonist-mediated feedback mechanisms has not been
examined.
This study utilized washed human platelets as a model to
define receptor-dependent and intracellular mechanisms of
LOX activation by acute physiological agonists. The data
shows (1) collagen or collagen-related peptide (CRP) signal-
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ing via glycoprotein VI (GPVI) acutely activates secretion of
12-H(P)ETE, in contrast to thrombin, ADP, and thromboxane
receptor (TP), (2) GPVI-stimulated 12-H(P)ETE synthesis
requires src-tyrosine kinases, Ca2 mobilization, and PI3-
kinase, and (3) GPVI-stimulated p12-LOX product genera-
tion is suppressed by PKC and PECAM-1. These data reveal
a central role for the FcR chain-associated GPVI collagen
receptor in activation of platelet 12-H(P)ETE generation and
implicate immune receptors in modulating LOX in the
vasculature.
Materials and Methods
Reagents
Collagen (Type I) was from Mascia Brunelli, Milan, Italy. Arachidonic
acid (AA), U46619, L-655238, 12-hydroxyeicosatetraenoic acid (12-
HETE), 15-hydroxy-11Z,13E-eicosadienoic acid (15-HEDE), baicalein,
and nordihydroguaiaretic acid (NDGA) were from Alexis Chemicals
Ltd. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic
acid (EGTA), 1,2-bis(2-aminophenoxy)ethane-N,N,N, N-tetraacetic
acid-acetoxymethyl ester (BAPTA/AM), FURA-2/AM, A23187, PP2,
p38-MAP kinase inhibitor (MKI), staurosporine, chelerythrine chloride,
and bis-indolymaleimide were from Calbiochem Ltd. All other reagents
were from Sigma Ltd, unless otherwise stated.
Preparation of Washed Human Platelets
Platelets were isolated as described28 from consenting donors who
were NSAID-free for 2 weeks before donating. Washed platelets
were resuspended in Ca2-freeTyrodes buffer (in mmol/L: 134 NaCl,
12 NaHCO3, 2.9 KCl, 0.34 Na2HPO4, 1 MgCl2, 10 HEPES, 5
glucose, pH 7.4).
Acute Activation of Platelets With Agonists and
Sample Preparation for HPLC
3108 platelets in 100 L Tyrodes, 1 mmol/L CaCl2, were stimu-
lated with either collagen (1 to 10 g/mL), CRP (0.05 to 10 g/mL)
(synthesized to a published sequence29), convulxin (1 g/mL protein
concentration) (a kind gift from Dr S.P. Watson, University of
Oxford, UK), thrombin (0.04 to 2.0 U/mL), the calcium ionophore,
A23187 (1 mol/L), arachidonic acid (20 mol/L), the thromboxane
mimetic, U46619 (10 mol/L), or ADP (5 mol/L) at 37°C with
agitation for 10 minutes. Experiments using signaling inhibitors
included a 10-minute preincubation step at 37°C before addition of
collagen or CRP (both 10 g/mL). Incubations were stopped by the
addition of 200 L ice-cold methanol and samples spun at 10 000g
for 10 minutes at 4°C. Supernatants containing 12-H(P)ETE were
recovered and supplemented with 200 ng 15(S)-HEDE per sample as
an internal standard.
Reverse Phase HPLC Analysis of Platelet
12-LOX Products
Samples (equivalent to 2107 cells per sample run) were separated
on a 150 mm4.6 mm, 5 m C18 ODS2 (Waters Ltd) column using
50% to 90% B over 20 minutes (Awater:acetonitrile:acetic
acid, 75:25:0.1, Bmethanol:acetonitrile:acetic acid, 60:40:0.1) at 1
mL/min. Absorbance was monitored at 235 nm. Products were
identified and quantified using 200 ng 12(S)-HETE standard run in
parallel under the same conditions.
Optical Aggregometry
Aggregation of 4108 washed platelets/mL in response to CRP (0.05
g/mL) was measured in siliconized-glass cuvettes at 37°C with
constant stirring in a PAP4 optical aggregometer (Bio/Data Corp).
Platelets were incubated with anti-PECAM-1 antibody (AB468, 1
g/mL) for 5 minutes, followed by cross-linking for 90 seconds with
F(ab)2 fragments of anti-IgG secondary antibody (30 g/mL).
Mouse monoclonal IgG (1 g/mL) plus F(ab)2 fragments of
anti-IgG secondary antibody (30 g/mL) were utilized as isotype
controls. CRP (0.05 g/mL) was then added and aggregation
responses measured.
FURA-2/AM Fluorescence
Washed platelets were incubated at 4108/mL with 2.5 mol/L
FURA-2/AM for 45 minutes before washing at 800g for 10 minutes.
Fluorescence was measured after agonist addition, using a Perkin
Elmer 50B fluorescence spectrophotometer at 37°C with stirring (ex,
340 nm, 380 nm; em, 509 nm).
Statistical Analysis
Data are representative of at least 3 separate donors, with samples
run in triplicate (Error bars are for meanSEM). Significance was
examined using an unpaired t test where P0.05 was considered
significant (denoted by * on figure). Activity in the presence of
inhibitors is expressed % relative to the collagen or CRP response, as
appropriate.
Results
Collagen and CRP Stimulate p12-LOX Product
Generation in Washed Human Platelets
Incubation of platelets with collagen or CRP led to 12-
H(P)ETE synthesis in a dose- and time-dependent manner
(Figure 1). 12-H(P)ETE generation in response to agonists
was confirmed by coelution with (1) authentic 12-H(P)ETE
standard, and (2) 12-H(P)ETE generated after arachidonate
activation of platelets. Furthermore, its synthesis was inhib-
ited by LOX inhibitors baicalein or NDGA (Figure 2A).
Peroxide analysis of platelet lysates determined that 12-
H(P)ETE comprised predominantly 12-HETE, with 12-
H(P)ETE content being 2.71.5% or 0.70.02% for colla-
gen or CRP, respectively (not shown). Collagen treatment
showed a lag-phase of approximately 25 seconds before a
rapid linear increase over 2 minutes, followed by a slower
phase of product generation from 2 to 10 minutes (Figure
1D). CRP showed a similar lag phase with product generation
increasing linearly over 1 to 5 minutes (Figure 1F). Synthesis
of 12-H(P)ETE did not require addition of exogenous fatty
acid or Ca2 ionophore, indicating that arachidonate substrate
originated from internal phospholipid hydrolysis. A crude
fraction of venom from Crotalus durissus terrificus contain-
ing convulxin, which selectively activates GPVI, also effi-
ciently stimulated 12-H(P)ETE generation (Table).
Incubation of platelets with thrombin ( 0.2 U/mL) failed
to stimulate 12-H(P)ETE synthesis (Table). Nonphysiological
concentrations of thrombin, up to 2.0 U/mL did stimulate,
although far less than collagen or CRP (not shown). Finally,
neither ADP nor the thromboxane A2 mimetic, U46619,
activated p12-LOX when added alone (Table). This was in
comparison to arachidonate or A23187 activated 12-
H(P)ETE synthesis, as previously shown.14
Ca2 Mobilization Is Necessary but Not Sufficient
for GPVI Stimulation of 12-H(P)ETE Synthesis
To examine whether Ca2 mobilization is required or sufficient
for GPVI-stimulated p12-LOX product generation, platelets
were first activated in Ca2-free buffer with EGTA (1 mmol/L)
to chelate extracellular Ca2, with/without BAPTA/AM
(10 mol/L). With EGTA alone, there was a significant 75%
decrease in collagen activation of p12-LOX. Additional prein-
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cubation with BAPTA/AM virtually abolished 12-H(P)ETE
synthesis (Figure 2B). Similarly, a substantial decrease in p12-
LOX activity in response to CRP was observed after Ca2
chelation, although differences were not statistically significant.
Separately, Ca2 mobilization in response to collagen (10 g/
mL), CRP (10 g/mL), or thrombin (0.1 U/mL) was determined
and compared. It was found that thrombin and CRP caused
similar elevations in cytosolic Ca2, which were approximately
two-fold higher than collagen (Figure 2C). Because thrombin is
ineffective at stimulating 12-H(P)ETE generation at this concen-
tration, Ca2 mobilization is required, but not sufficient to
stimulate p12-LOX turnover.
L-655238 Inhibits CRP-Mediated p12-LOX
Product Generation
When incubated with washed platelets, the translocation
inhibitor L-655238 (10 mol/L) significantly inhibited CRP-
stimulated 12-H(P)ETE generation (Figure 2D).
CRP and Collagen Stimulation of 12-H(P)ETE
Generation Requires Signaling by
Tyrosine Kinases
To examine the potential role of tyrosine kinases in p12-LOX
activation, staurosporine and the src-family tyrosine kinase
inhibitor, PP2, were utilized.30,31 Preincubating platelets with
20 mol/L staurosporine before collagen or CRP addition
caused an approximate 85% inhibition of H(P)ETE genera-
Figure 1. Collagen and CRP stimulate 12-H(P)ETE synthesis in a
dose- and time-dependent manner in washed human platelets. A,
Generation of 12-H(P)ETE by collagen-activated platelets. 3108
platelets in Tyrodes buffer (pH 7.4) and 1 mmol/L CaCl2 were acti-
vated with 10 g/mL collagen. LOX products were separated on
reverse-phase HPLC as described in Materials and Methods. A inset,
UV spectrum of platelet-derived 12-H(P)ETE peak showing absorption
maximum at 235 nm. B, Generation of 12-H(P)ETE by collagen or
CRP-activated platelets. Overlaid chromatograms showing
12-H(P)ETE generation for (i) CRP (10 g/mL), (ii) collagen (10 g/mL),
and (iii) untreated platelets. C, Dose dependence of collagen activation
of p12-LOX. Platelets were incubated with 1 to 10 g/mL collagen for
10 minutes. D, Time dependence of collagen activation of p12-LOX.
Platelets were incubated with 10 g/mL collagen for 1 to 10 minutes.
E, Dose dependence of CRP activation of p12-LOX. Platelets were
incubated with 1 to 10 g/mL CRP for 10 minutes. F, Time depen-
dence of CRP activation of p12-LOX. Platelets were incubated with 10
g/mL CRP for 1 to 10 minutes.
Figure 2. Effects of LOX, calcium signaling inhibitors, and a LOX
translocation inhibitor on collagen/CRP-mediated p12-LOX
activity. All samples were analyzed for 12-H(P)ETE content as
described. A, Inhibition of p12-LOX by LOX inhibitors. Platelets
were preincubated with the LOX inhibitors baicalein (0.3 mol/L)
or NDGA (60 mol/L) before adding collagen or CRP. Platelets:
a, collagen; b, collagenbaicalein; c, collagenNDGA; d,
CRP; e, CRPbaicalein; f, CRPNDGA. B, Requirement
for calcium signaling in collagen or CRP activation of p12-LOX.
Platelets were preincubated with calcium chelators (1 mmol/L
EGTA and/or 10 mol/L BAPTA/AM) before addition of collagen
or CRP. Platelets: a, collagen; b, collagenEGTA; c,
collagenEGTABAPTA/AM; d, CRP; e, CRPEGTA; f,
CRPEGTABAPTA/AM. C, Calcium mobilization in response
to agonists. Platelets were labeled with FURA-2 as described in
Materials and Methods. Background fluorescence ratios were
subtracted from all samples. Platelets: a, collagen (10 g/mL);
b, CRP (10 g/mL); c, thrombin (0.1 U/mL). D, LOX translo-
cation inhibitor, L-655238, inhibits CRP-mediated p12-LOX
product generation. Platelets were preincubated with 10 mol/L
L-655238 before adding CRP. Platelets: a, CRP; b, CRPL-
655238. *P0.05 using unpaired t test.
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tion. (Figure 3A). Preincubating platelets with PP2 (0 to
50 mol/L) before collagen or CRP addition caused signifi-
cant dose-dependent inhibition of p12-LOX product genera-
tion. (Figure 3B).
CRP Mediated 12-H(P)ETE Synthesis Is Only
Partially Affected by p38-MAP Kinase Inhibition
Preincubating platelets with MKI (100 nmol/L) partially
inhibited CRP, but was without effect on collagen-activated
H(P)ETE synthesis (Figure 3C).
CRP and Collagen Stimulation of 12-H(P)ETE
Synthesis Requires Signaling by PI3-Kinase
After GPVI activation, PI3-kinase binds to the phosphorylat-
ed FcR chain and yields PIP3.32 Preincubation of platelets
with the PI3-kinase inhibitor wortmannin (100 nmol/L) sub-
stantially inhibited collagen and CRP-mediated p12-LOX
activity (Figure 3D), implicating this pathway in GPVI-
dependent p12-LOX activation.
PKC Inhibitors Potentiate Agonist-Mediated
12-H(P)ETE Generation
PKC is associated with phosphorylation of cytosolic PLA2
and Ca2 mobilization in platelets.33,34 Two specific PKC
inhibitors, bis-indolymaleimide and chelerythrine chloride (1
to 10 mol/L), potentiated collagen and CRP-mediated p12-
LOX. Also, bis-indolymaleimide inclusion with U46619, but
not ADP, stimulated 12-H(P)ETE synthesis to levels similar
to collagen alone (Figure 4C).
Requirement of PGHS-1 or ADP for Collagen
and CRP Activation of p12-LOX
Product Generation
Although unable to directly activate 12-H(P)ETE synthesis
alone (Table), secondary mediators including ADP and
U46619, may modulate GPVI-dependent activation.35,36 In-
domethacin (10 mol/L) or aspirin (10 mmol/L) were with-
out effect on collagen stimulation, but caused a significant
decrease in the CRP response, suggesting that GPVI activa-
tion of 12-H(P)ETE generation may involve signaling by
TXA2 (Figure 5A). Preincubation of platelets with 1 U/mL
apyrase caused significant inhibition of collagen or CRP-
Quantification of 12-H(P)ETE Generation by Platelets
Treatment
ng 12-H(P)ETE per
2108 platelets	
Platelets only 0.00
Plateletscollagen (10 g/mL) 6.501.50
PlateletsCRP (10 g/mL) 30.610.29
Plateletsthrombin (0.2 U/mL) 0.500.70
Plateletsconvulxin (1 g/mL) 19.504.80
PlateletsA23187 (1 mol/L) 17.030.10
Plateletsarachidonate (20 mol/L) 94.806.10
PlateletsU46619 (10 mol/L) 0.900.90
PlateletsADP (5 mol/L) 0.040.05
Platelets were stimulated with various agonists before being analyzed by
reverse-phase HPLC for 12-H(P)ETE. Data shown are for meanSEM, n3.
Figure 3. Tyrosine kinase and PI3-kinase inhibitors block col-
lagen or CRP activation of p12-LOX. A p38-MAP kinase in-
hibitor partially inhibits CRP-mediated p12-LOX activity. All
samples were analyzed for 12-H(P)ETE content as described.
A, Staurosporine inhibits collagen or CRP activation of p12-
LOX. Platelets were preincubated in the presence of stauro-
sporine (20 mol/L) before adding collagen or CRP. Platelets:
a, collagen; b, collagenstaurosporine; c, CRP; d,
CRPstaurosporine. B, Src-family tyrosine kinase inhibition
blocks collagen or CRP activation of p12-LOX. Platelets were
preincubated with the src-family tyrosine kinase inhibitor, PP2
(0 to 50 mol/L), before adding collagen or CRP. Platelets: a,
collagen; b, collagenPP2 (5 mol/L); c, collagenPP2
(10 mol/L); d, collagenPP2 (50 mol/L); e, CRP; f,
CRPPP2 (5 mol/L); g, CRPPP2 (10 mol/L); h,
CRPPP2 (50 mol/L). C, p38-MAP kinase inhibition par-
tially blocks CRP-mediated p12-LOX activation. Platelets
were preincubated with the p-38 MAP kinase inhibitor, MKI
(100 nmol/L), before addition of collagen or CRP. Platelets: a,
collagen; b, collagenMKI; c, CRP; d, CRPMKI. D,
PI3-kinase inhibition blocks collagen or CRP activation of
p12-LOX. Platelets were preincubated with the PI3-kinase
inhibitor, wortmannin (100 nmol/L), before the addition of col-
lagen or CRP. Platelets: a, collagen; b, collagen  wort-
mannin; c, CRP; d, CRPwortmannin. *P0.05 using
unpaired t test.
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stimulated activity (Figure 5B). However inhibition of the
collagen response was greater, suggesting ADP signaling
may be more important in collagen activation of 12-H(P)ETE
synthesis via receptors other than GPVI.
Alterations in 12-H(P)HETE Esterification Do Not
Explain Changes in p12-LOX Product Detection
After their generation, H(P)ETEs can be esterified into
membrane phospholipids. To examine whether changes in
lipid esterification or hydrolysis in the presence of inhibitors
could account for the data herein, samples were analyzed for
12-H(P)ETE before and after alkaline hydrolysis. No signif-
icant differences were found for controls or samples treated
with PP2, wortmannin, bis-indolymaleimide, or aspirin, indi-
cating that 12-H(P)ETE esterification is not taking place
during the time course of our assays (data not shown).
Activation of PECAM-1 in Platelets Inhibits
CRP-Mediated p12-LOX Activity
PECAM-1 signaling is stimulated by receptor oligomeriza-
tion, which is achieved in platelets by antibody cross-
linking.37 Stimulation of PECAM-1 before CRP addition
caused marked inhibition of platelet aggregation, as previ-
ously found (Figure 6A). Similarly PECAM-1 activation
inhibited CRP-mediated 12-H(P)ETE synthesis by approxi-
mately 50% (Figure 6B). Conversely, isotype control anti-
body added with cross-linking F(ab)2 or cross-linking F(ab)2
added alone caused potentiation of p12-LOX activity. This
reveals PECAM-1 as a negative regulator of GPVI-dependent
p12-LOX activation.
Discussion
Using human platelets, a novel receptor-dependent signaling
pathway for 12-H(P)ETE synthesis was characterized that
utilizes the collagen receptor GPVI. Requirements for GPVI-
activation of p12-LOX included src-tyrosine kinases, PI3-
kinase, Ca2 mobilization, and p12-LOX translocation,
whereas PKC and PECAM-1 were inhibitory.
Figure 4. PKC inhibition potentiates collagen or CRP-mediated
p12-LOX product generation, and enhances U46619 (but not
ADP)-mediated p12-LOX activity. All samples were analyzed for
12-H(P)ETE content as described. Platelets were preincubated
in the presence of PKC inhibitors chelerythrine chloride or bis-
indolymaleimide (both 1 to 10 mol/L) before adding collagen or
CRP. A, Collagen activation of p12-LOX is potentiated by PKC
inhibition. Platelets: a, collagen; b, collagenchelerythrine
(1 mol/L); c, collagenchelerythrine (3 mol/L); d,
collagenchelerythrine (10 mol/L); e, collagenbis-
indolymaleimide (1 mol/L); f, collagenbis-indolymaleimide
(3 mol/L); g, collagenbis-indolymaleimide (10 mol/L). B,
CRP activation of p12-LOX is potentiated by PKC inhibition.
Platelets: a, CRP; b, CRPchelerythrine (5 mol/L); c,
CRPchelerythrine (10 mol/L); d, CRPbis-
indolymaleimide (5 mol/L); e, CRPbis-indolymaleimide
(10 mol/L). C, Bis-indolymaleimide potentiates U46619-
mediated (but not ADP-mediated) p12-LOX activity. Platelets: a,
ADP (5 mol/L); b, ADPbis-indolymaleimide (20 mol/L); c,
U46619 (10 mol/L); d, U46619bis-indolymaleimide
(20 mol/L). *P0.05 using unpaired t test; for C, % control
refers to collagen response.
Figure 5. Role of secondary mediators in collagen or CRP stim-
ulation of p12-LOX. All samples were analyzed for 12-H(P)ETE
content as described. A, PGHS-1 signaling is involved in CRP
but not collagen activation of p12-LOX. Platelets were preincu-
bated with either indomethacin (10 mol/L) or aspirin
(10 mmol/L) before adding collagen or CRP. Platelets: a, colla-
gen; b, collagenindomethacin; c, collagenaspirin; d,
CRP; e, CRPindomethacin; f, CRPaspirin. B, Apyrase
inhibits collagen or CRP-mediated p12-LOX activation. Platelets
were incubated with the ADP scavenger, apyrase (1 U/mL),
before adding collagen or CRP. Platelets: a, collagen; b,
apyrasecollagen; c, CRP, d, apyraseCRP. *P0.05
using unpaired t test.
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Collagen or CRP activated 12-H(P)ETE synthesis in a
dose- and time-dependent manner (Figure 1), implicating
FcR chain–coupled GPVI as a specific p12-LOX–activating
pathway in human platelets. Collagen utilizes several cell
surface receptors including: GPVI, 21 integrin, GP1b, and
bound von Willebrand factor.38,39 However, activation by
CRP indicates that GPVI signaling alone is sufficient to
activate p12-LOX. Conversely, thrombin did not activate
unless added in amounts far higher than required for platelet
aggregation and degranulation. Finally, neither TP receptor
signaling nor ADP could activate 12-H(P)ETE generation
alone (Table, Figure 5), although U46619 did stimulate in the
presence of the PKC inhibitor, bis-indolymaleimide, suggest-
ing PKC may negatively regulate PGHS-1–dependent acti-
vation of p12-LOX activity in platelets (Figure 4C).
GPVI is a platelet-specific collagen receptor whose impor-
tance in vascular collagen signaling is highlighted by obser-
vations that sequence dimorphisms are associated with in-
creased risk of myocardial infarction.40,41 GPVI closely
associates with an ITAM present on the FcR chain that
activates tyrosine kinases via adapter molecules such as
SLP-76.32,42–44 Activating GPVI triggers PI3-kinase turnover,
whose products activate phospholipase C2 (PLC2).45,46
PLC forms DAG and IP3, which activate PKC and Ca2
mobilization, respectively.47,48 GPVI also causes phosphory-
lation of p38-MAP kinase, which can directly activate platelet
cytosolic PLA2, a potential source of arachidonate substrate
for p12-LOX.34,49
To explore requirements for GPVI activation of p12-LOX,
signaling inhibitors were also utilized. Potent inhibition of
CRP-mediated 12-H(P)ETE synthesis by BAPTA/AM and
EGTA implicated Ca2 mobilization, which could activate
p12-LOX by stimulation of p12-LOX translocation (Figure
2B).50,51 In agreement, a translocation inhibitor, L-655238,
substantially inhibited GPVI-dependent 12-H(P)ETE synthe-
sis similar to previous reports using collagen (Figure 2D).15
However, Ca2 mobilization is not in itself sufficient for
p12-LOX activation, because a concentration of thrombin
that did not cause 12-H(P)ETE synthesis caused significantly
greater Ca2 mobilization than collagen (Figure 2C).
GPVI stimulation of 12-H(P)ETE generation was inhibited
by PP2, staurosporine, and wortmannin, implicating src-
tyrosine kinases and PI3-kinase in p12-LOX activation (Fig-
ure 3). Although these pathways are already known to be
activated via GPVI, they have not been previously reported to
activate H(P)ETE synthesis in mammalian cells, and provide
novel insights into intracellular signaling pathways that mod-
ulate LOX product formation. In contrast, an inhibitor of p38
MAP kinase (MKI) did not inhibit collagen, and only slightly
inhibited CRP-dependent H(P)ETE generation (Figure 3C).
Secondary mediators such as TXA2 and ADP are involved
in collagen signaling in platelets and were found to variably
regulate collagen or CRP activation of p12-LOX (Figure 5).52
Apyrase significantly inhibited CRP and collagen-mediated
12-H(P)ETE synthesis, but with a greater effect on collagen
activation (Figure 5B). Indomethacin or aspirin partially
blocked CRP but not collagen-mediated 12-H(P)ETE gener-
ation (Figure 5A). Collectively, this indicates that stimulation
of H(P)ETE synthesis via GPVI involves TP signaling, but
collagen activation may involve additional receptors signal-
ing independently of the TP receptor and a greater involve-
ment of ADP.38,39
Two PKC inhibitors dose-dependently enhanced collagen/
CRP-mediated 12-H(P)ETE synthesis, indicating that PKC
negatively regulates GPVI-dependent p12-LOX product gen-
eration (Figure 4A). Also, PKC inhibition potentiated
U46619 but not ADP stimulation of 12-H(P)ETE generation
(Figure 4C). It has been previously shown that PKC is
required for U46619 but not ADP-induced platelet activa-
tion.53 Inhibition by PKC may involve cross-talk between
PKC or  and Bruton’s or Fyn tyrosine kinases in platelets,
which was recently described.54–56
In the vasculature, the balance between two distinct sig-
naling motifs, termed ITAM and ITIM, has impact on
regulating vascular cell function.57 In platelets, ITAM present
on the FcR chain coupled to GPVI is activated through
phosphorylation by src-family tyrosine kinases. This is inhib-
ited by proteins possessing ITIM, for example, PECAM-
1.58,59 Herein, cross-linking studies utilizing antibodies spe-
cific for PECAM-1 demonstrated substantial suppression of
GPVI-stimulation of 12-H(P)ETE synthesis. Unexpectedly,
isotype controls (omitting anti-PECAM-1 antibodies),
showed that cross-linking antibodies alone could potentiate
CRP stimulation of 12-H(P)ETE synthesis. Although not
understood, this may result from interactions of F(ab)2
anti-IgG secondary antibody with sites on the platelet surface
unrelated to PECAM-1. The observation that cross-linking
using specific anti–PECAM-1 antibody markedly inhibits
GPVI-mediated 12-H(P)ETE synthesis demonstrates a novel
Figure 6. PECAM-1 activation inhibits CRP-mediated p12-LOX
activation in washed platelets. Washed platelets were incubated
with anti-PECAM antibody (AB468), anti-mouse IgG isotype
control, and cross-linking F(ab)2 anti-IgG secondary antibody,
activated by CRP, and 12-H(P)ETE levels determined. A, Optical
aggregometry of washed platelets (4108/mL) treated with (i)
CRPanti PECAM-1F(ab)2 anti-IgG, (ii) CRPisotype
controlF(ab)2 anti-IgG, and (iii) CRP alone. B, Washed plate-
lets were incubated with (a) CRP alone, (b) CRPanti PECAM-
1F(ab)2 anti-IgG; (c) CRPisotype controlF(ab)2 anti-IgG; (d)
CRPF(ab)2 anti-IgG.
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function for PECAM-1 and a role for ITIM/ITAM-containing
immune receptors in modulating 12-H(P)ETE synthesis (Fig-
ure 6).
This study presents the first detailed intracellular charac-
terization of a specific receptor-dependent signaling pathway
that acutely activates LOX turnover in mammalian cells, and
provides a novel link between immune receptor signaling and
lipid oxidation in the vasculature.
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